Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Addiction Medicine Psychiatrists (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 13, 2007
Do not lose heart--it causes weight loss
Analysis of: Wyeth's Schizophrenia Pill Is Rejected by U.S. FDA | www.bloomberg.com
Author: GLG Expert Contributor
Although the atypical antipsychotics are developed for the treatment of psychosis, in reality they are now most often used as adjunctive treatments to antidepressants and mood stabilizers, for control of anxiety, for enhancing sleep, and in treatment of personality disorders that involve behavioral...
August 10, 2007
We have the data, but will it change behavior?
Analysis of: Crystal-Clear Exercise Advice From U.S. Heart, Sports Medicine Groups | www.webmd.com
Author: GLG Expert Contributor
This is a very clear and succinct pronouncement from two august organizations.  There is little room for misinterpretation.  However, clear pronouncements do not a change in behavior make.
August 10, 2007
Rational drug development is refreshing
Analysis of: Successful Proof-of-Concept With Actelion's Orexin Receptor Antagonist in Patients Suffering From Primary Insomnia -- First Demonstration of Key Role of Orexin System in Humans Suffering From Sleep Disorders | www.primenewswire.com
Author: GLG Expert Contributor
Physiologically-based management of primary insomnia is a step in the right direction, as is the advent of new sleep medications that address other than the GABA system.  Development of these medications follow the strategy of modulating a brain orexin neurons with Orexin-OX1/OX2 receptor...
July 25, 2007
Antidepressant medications are not for everyone and these medications are not all the same
Analysis of: The Unmedicated Mind: Backlash against antidepressants is fueling new interest in alternative treatments | online.wsj.com
Author: GLG Expert Contributor
The backlash against antidepressants is not a bad thing if depression is addressed in other ways that work.  Doubtless such a backlash will reduce antidepressant drug sales, but it will lead to exciting opportunities in health maintenance and holistic medicine.  The bottom line--depression...
July 24, 2007
Rimonabant psychiatric "side effects" need to be viewed in terms of any existing psychopathology in patients for whom it is prescribed
Analysis of: UK Regulator: 1 Person in 10 on Acomplia Experiences Psychiatric Side Effects | www.acompliareport.com
Author: GLG Expert Contributor
Patients with obesity are the predominant target of rimonobant therapy in the U.K.  Patients with obesity are at significantly increased risk for psychopathology, including depression. 
July 24, 2007
Aripiprazole: jockeying for position
Analysis of: ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder | www.pipelinereview.com
Author: GLG Expert Contributor
Aripiprazole is before the FDA with priority status and will (probably) be approved for an adjunctive role in treatment of major depressive disorder.  Add to that its approved use in bipolar disorder and its frequent use in anxiety, it still does not have much to offer that its competition risperidone,...
July 16, 2007
I can hardly wait to see the advertising campaign for this one!
Analysis of: J&J Hasn't Given Up on Sex Pill for Men | www.forbes.com
Author: GLG Expert Contributor
With medications like this medical necessity and lifestyle improvement are becoming increasingly blurred.  People will pay handsomely to improve their sexual satisfaction.  Moreover, companies who cater to these needs stand to make incredible profits.  This is a "free country" and people...
July 12, 2007
A potent analgesic without addiction potential?
Analysis of: Adolor Corporation Initiates First of Three Proof of Concept Studies of Novel Delta Opioid Agonist for the Management of Pain | www.pipelinereview.com
Author: GLG Expert Contributor
A series of compounds were prepared by Adolor which have significant affinity for the delta opioid receptor and presumably not the mu or kappa receptors.  Since the latter two receptors are predominantly responsible for toxicity associated with opioid drugs, the notion is that ADL5859 will have...
July 12, 2007
Docs just got to prescribe otherwise why recognize a problem? Let's not throw out the baby with the bath water!
Analysis of: Pediatric SSRI Use, Depression Diagnosis Dropped After FDA Advisory | www.medscape.com
Author: GLG Expert Contributor
Why should the rate of pediatric depression decrease just because the FDA has issued a black box warning about the use of SSRIs in children and young adults?  Nevertheless, this was the finding of a recent article in the Journal of the American Psychiatric Association.
July 12, 2007
Unexpected and disappointing negative outcomes for Gabapentin GR (TM)
Analysis of: Depomed announces results of phase 3 clinical trial for Gabapentin GR(TM) in postherpetic neuralgia | www.pipelinereview.com
Author: GLG Expert Contributor
Gabapentin has yielded very good results for the treatment of neuropathic pain as documented in the literature, and supported by my personal clinical experience.  This Phase 3 clinical trial of Gabapentin GR(TM) is unexpected and the question it raises is whether this new formulation...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 132

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747